Shots:
- STADA acquires Lobsar and its innovative therapy to foster its footprints in specialty pharmaceuticals. The acquisition complements STADA’s portfolio and expertise in the treatment of late-stage Parkinson’s disease
- With the acquisition, STADA gain rights to a triple fixed combination (levodopa/carbidopa/ entacapone) delivered via modern pump technology, already launched in Nordic countries
- Levodopa, carbidopa and entacapone infusion therapy is inserted in the small intestine through a discreet, wearable pump. The infusion is approved in Sweden, Denmark, Norway, and Finland, while STADA is currently submitting approval applications to launch the therapy in multiple EU markets
Click here to read full press release/ article | Ref: STADA | Image: S
The post STADA Expands its Specialty Footprint with the Acquisition of Lobsor Pharmaceuticals first appeared on PharmaShots.
